SLC5A2 and diabetic kidney disease: In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, finerenone, a novel, nonsteroidal, selective MRA, reduced the urine albumin-to-creatinine ratio in patients with DKD, regardless of whether the patients received SGLT2 inhibitors or GLP-1 RA at the baseline, with no heterogeneity [53,54].